Blog | Association for Accessible Medicines

AAM's Strategic Priorities for 2019

Nov 28, 2018 | Jewel Smith

You’re Invited! AAM Strategic Priorities Planning for the New Year

BCBS: It’s time to CREATE more choices & lower drug prices

Nov 28, 2018 | Chip Davis

BCBS: It’s time to CREATE more choices & lower drug prices

Generics and Biosimilars

Nov 27, 2018 | David Gaugh

Preliminary Recommendations for Addressing Drug Shortages

Prescription Drug Safety: Education and Impact

Oct 30, 2018 | Chip Davis

Prescription Drug Safety: Education and Impact

Women in Health Policy Happy Hour October 2018

Oct 29, 2018 | Kristin Murphy

Women in Health Policy Gather at AAM

FDA Approvals - Generic Drugs

Oct 10, 2018 | Chip Davis

Generic and Biosimilars Approvals Are Only Half the Story

New NAFTA - Proposed US-Mexico-Canada Agreement (USMCA)

Oct 9, 2018 | Jeff Francer

Op-Ed: The New NAFTA Could Thwart President's Promise to Lower Prescription Drug Costs

Direct Relief and AAM - Generic Prescriptions, AAM Member

Oct 4, 2018 | Rachel Schwartz

Prescription for Hope: AAM Members and Direct Relief

Sep 21, 2018 | Michael Brzica

$13.4 Billion a Year! Brand “Shenanigans” Are Costing Patients More Than Ever

Ariel Leaty, cancer patient, generic drug savings

Sep 20, 2018 | Erica Klinger

Generic Prescriptions Save Lives… and Money, Too

FDA's Competitive Generic Therapy (CGT) Designation

Sep 19, 2018 | Erica Klinger

10 Takeaways from the Savings Report

AAM President & CEO Chester "Chip" Davis, Jr. delivers the State of the Industry Address

Sep 13, 2018 | Rachel Schwartz

Recap: Highlights From the First GRx+Biosims Conference